About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ARWR - Arrowhead Pharmaceut...| Previous Close | $66.12 | Open | $65.94 |
| Volume | 714.5K | Market Cap | 6.882B |
| Yield | Last Dividend |
| Arrowhead Pharmaceuticals EPS misses by ... | 3:02 PM |
| No summary available. | |
| Arrowhead Pharmaceuticals Reports Fiscal... | 3:00 PM |
| Conference Call and Webcast Today, August 5, 2021 at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Arrowhead Pharmaceuticals, Inc. (... | |
| Defender Capital, LLC. Buys Fortive Corp... | 07/29/21 |
| Related Stocks: FTV , CFX , OCX , KMI , MSFT , LNDC , INTC , PLTR , PFE , MLM , BE , PTN , VNT , CDMO , ARWR , | |
| Arrowhead Pharmaceuticals Receives Break... | 07/29/21 |
| - Full enrollment reached in Phase 2 SEQUOIA study of ARO-AAT PASADENA, Calif. --(BUSINESS WIRE)--Jul. 29, 2021-- Arrowhead Pharmaceuticals, Inc. (NAS... | |
| Oligonucleotide Therapeutics Market 2021... | 07/22/21 |
| This report studies the Oligonucleotide Therapeutics Market with many aspects of the industry such as market size, market status, market trends and fo... | |
| Arrowhead Pharmaceuticals to Webcast Fis... | 07/14/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead host a webcast and conference call on August 5, 2021, at 4:30 p.m. ET to discuss fiscal 2021 th... | |
| Arrowhead Pharmaceuticals Reports Induce... | 07/14/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | |
| Biotech M&A may heat up with potential t... | 07/11/21 |
| No summary available. | |
| Arrowhead Pharmaceuticals Inc. Shares Cl... | 07/09/21 |
| Arrowhead Pharmaceuticals Inc. (ARWR) shares closed this week 23.1% lower than it did at the end of last week. The stock is currently flat year-to-da... | |
| Arrowhead Pharmaceuticals Dives On Safet... | 07/06/21 |
| No summary available. | |
| Arrowhead''s Big Sell-Off Presents Buyin... | 07/06/21 |
| The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright... | |
| Arrowhead''s ARO-HIF2 Shows Early Signs ... | 07/06/21 |
| Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell re... | |
| RBC Capital Stick to Their Buy Rating fo... | 07/05/21 |
| RBC Capital Stick to Their Buy Rating for Arrowhead Pharmaceuticals | |
| Arrowhead Pharma favored at H.C. Wainwri... | 07/03/21 |
| No summary available. | |
| Here''s Why Arrowhead Pharmaceuticals St... | 07/02/21 |
| A paused clinical trial with an important asset wasn''t what investors wanted to hear today. | |
| Arrowhead Pharmaceuticals Pauses Test of... | 07/02/21 |
| Arrowhead''s move comes after a toxicology study in rats contained unexpected signals of local lung inflammation, the company says. | |
| Arrowhead rocked by animal tox issues ag... | 07/02/21 |
| Arrowhead Pharmaceuticals faced a reckoning back in 2016 when it was forced to scrap its entire clinical pipeline after reporting deaths in a non-huma... | |
| Mid-Day Market Update: Dow Surges Over 1... | 07/02/21 |
| Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to | |
| Arrowhead Stock Drops After RNAi Therape... | 07/02/21 |
| Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC... | |
| Arrowhead Pauses ARO-ENaC Phase 1/2 Clin... | 07/02/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study | |
| Arrowhead Presents Additional Clinical D... | 06/26/21 |
| PASADENA, Calif. --(BUSINESS WIRE)--Jun. 26, 2021-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented additional positive interim 48-week ... | |
| Arrowhead Presents Preclinical Data on A... | 06/25/21 |
| PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals presented preclinical data on the development of ARO-DUX4 at 28th Annual FSHD S... | |
| H.C. Wainwright Stick to Their Buy Ratin... | 06/24/21 |
| H.C. Wainwright Stick to Their Buy Rating for Arrowhead Pharmaceuticals | |
| Arrowhead posts positive data from early... | 06/23/21 |
| No summary available. | |
| Arrowhead and Horizon team up in potenti... | 06/21/21 |
| No summary available. | |
| Dosing underway in Arrowhead Pharma''s m... | 06/03/21 |
| No summary available. | |
| Arrowhead Pharmaceuticals Initiates Phas... | 06/02/21 |
| Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-A... | |
| Arrowhead Pharmaceuticals to Participate... | 06/02/21 |
| PASADENA, Calif.(BUSINESS WIRE)$arwrArrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following... | |
| Arrowhead Pharmaceuticals to Participate... | 06/01/21 |
| Arrowhead Pharmaceuticals Inc. announced that it is scheduled to participate in the following upcoming events | |
| 22 biotech companies that will likely ge... | 05/24/21 |
| Hello, Welcome to Insider Healthcare. I''m Lydia Ramsey Pflanzer, and today in healthcare news: 22 biotech companies that will likely get bought; Why ... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Value Investing | Flying Colors | 88.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
